Readiness of high-risk populations in the HIV Network for Prevention Trials to participate in HIV vaccine efficacy trials in the United States
Authors:
- Patrick HeagertyPHPatrick Heagerty
- Amy SheonASAmy Sheon
- Susan BuchbinderSBSusan Buchbinder
- Connie CelumCCConnie Celum
- John M. DouglasJDJohn M. Douglas
- Michael GrossMGMichael Gross
- Michael MarmorMMMichael Marmor
- Kenneth MayerKMKenneth Mayer
- David MetzgerDMDavid Metzger
- George SeageGSGeorge Seage
- 1 May 1998
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 12 (7) , 785-793
Abstract
To determine the willingness of populations at high risk of HIV-1 infection to participate in HIV vaccine efficacy trials, determine factors influencing decision-making, and evaluate knowledge levels of vaccine trial concepts. Cross-sectional study. HIV-1-negative homosexual men, male and female injecting drug users and non-injecting women at heterosexual risk were recruited in eight cities in the United States (n = 4892). A substantial proportion of the study population (77%) would definitely (27%) or probably (50%) be willing to participate in a randomized vaccine efficacy trial. Increased willingness was associated with high-risk behaviors, lower education level, being uninsured or covered by public insurance, and not having been in a previous vaccine preparedness study. Altruism and a desire for protection from the vaccine were major motivators for participation. Major concerns included positive HIV-1 antibody test due to vaccine, safety of the vaccine, and possible problems with insurance or foreign travel. Baseline knowledge of vaccine trial concepts was low. It is likely that high-risk volunteers will be willing to enroll in HIV vaccine efficacy trials. A variety of participant and community educational strategies are needed to address participant concerns, and to ensure understanding of key concepts prior to giving consent for participation.Keywords
This publication has 9 references indexed in Scilit:
- Willingness to Participate in HIV-1 Vaccine Efficacy Trials and the Effect of Media Events Among Gay and Bisexual Men in New York CityJAIDS Journal of Acquired Immune Deficiency Syndromes, 1997
- Feasibility of Human Immunodeficiency Virus Vaccine Trials in Homosexual Men in the United States: Risk Behavior, Seroincidence, and Willingness to ParticipateThe Journal of Infectious Diseases, 1996
- The feasibility of HIV-1 vaccine efficacy trials among gay/bisexual men in New York City: Project ACHIEVEAIDS, 1996
- HIV vaccines: where we are and where we are goingThe Lancet, 1996
- Interest among Gay/Bisexual Men in Greater Boston in Participating in Clinical Trials of Preventive HIV VaccinesJAIDS Journal of Acquired Immune Deficiency Syndromes, 1996
- Weight Loss Associated with HIV Seroconversion Among Injection-Drug UsersJAIDS Journal of Acquired Immune Deficiency Syndromes, 1996
- Candidate AIDS VaccinesNew England Journal of Medicine, 1995
- Preventing Discrimination against Volunteers in Preventive HIV Vaccine Efficacy Trials: Conference SummaryAIDS Research and Human Retroviruses, 1995
- HIV vaccine trials: will intravenous drug users enroll?American Journal of Public Health, 1994